- Managed and overviewed Study Start Up in 36 countries across Europe, Middle East, Africa, North America, Latin America, Asia Pacific
- Go-to Resource for SSU Pre-awarding: Proposals and Bid-defense meetings
- Experienced with multiple studies/programs in Complex Innovative Designs and Expanded Access Pathways
- Subject Matter Expert in Regulatory Transition
Archives: Speakers
Jung Won Jung
HyeJung Yang
Hyejung Yang is the Team Leader of the Clinical New Drug Team at Daewoong Pharmaceutical. She has over 14 years of experience in global clinical development, leading Phase I–III trials across multiple therapeutic areas, with a particular focus on new drug development projects. She has extensive expertise in project leadership, study start-up, investigational product management, and global site/vendor communication. As a clinical team leader, she has directed cross-functional teams and contributed to IND submissions, ensuring successful execution of global clinical trials.
Alicia Kim
– 23Y Clinical Trial & New Drug Development Expert Professional
– Global & Local Trials Experiences including the 1st Phase 2 COVID-19 New Oral-drug Trial PM in Korea & USA
– Global CROs and Local Pharmacies Experiences
– All-round Experts in Clinical Trials (Medicines & Devices)
YongGwan Kim
- Associate Director-Trial Delivery Leader, Medical Affairs Delivery Unit, J&J Innovative Medicine
- Masters Degree of Supply Chain Management, MBA, Inha University
Sangho Ma
Dr. Sang Ho Ma, Ph.D. in Pharmacy, is Vice President of Development at A&J Science and a member of the Expert Committee of the Ministry of Food and Drug Safety (MFDS). With over 20 years of
experience in drug discovery and development, including CMC, regulatory affairs, and clinical research, he provides expertise across immuno-oncology, rare diseases, infectious diseases, and vaccines.
Jaeyoung Hyun
Jaeyoung Hyun serves as Head of the Business Development Unit at GCCL(Global Clinical Central Lab), a leading central lab in Asia Pacific specializing in clinical trial sample analysis for global pharmaceutical and biotech sponsors. In this role, he oversees domestic and global client engagement, strategic sales, and partnership development, driving GCCL’s growth and international presence.
With a long-standing career in domestic sales and business development within the pharmaceutical and healthcare industries, Mr. Hyun has cultivated deep expertise in fostering client relationships, shaping commercial strategies, and supporting multinational clinical programs. His professional background includes extensive collaboration with pharma and biotech companies, with a focus on overcoming logistical barriers in clinical sample management—an area he will address in his OCT Korea 2025 session, “Optimizing Central Lab Supply Chains: Overcoming Logistical Barriers in Clinical Sample Management.”
Amy Jung Hyun LEE
Amy is a seasoned imaging clinical trial expert with a PhD in Biomedical Sciences and extensive experience in the design, execution, and evaluation of imaging across multiple therapeutic areas, including oncology, ophthalmology, neurology, dermatology, musculoskeletal, and gastroenterology. With nearly a decade of leadership in managing imaging projects, she has worked with global pharmaceutical companies, leading CROs, and major hospitals worldwide. Her career journey spans roles from imaging project manager to CEO of a Singapore-based imaging CRO, and she now brings her expertise to a global imaging CRO.
Choong Hee LEE
Eunah Paek
Ms. Eun-Ah Paek, Executive Director at Boryung Co., Ltd., majored in Pharmacy at Sookmyung Women’s University, where she also earned her Master’s degree in Pharmacology. She subsequently completed her doctoral coursework in Pharmacoepidemiology at Sungkyunkwan University.
She previously served as a project leader for central nervous system (CNS) drug development at SK Biopharm and is currently in charge of clinical trials, post-marketing clinical research, pharmacovigilance, and medical writing as the head of the Clinical Division at Boryung.
With over 30 years of experience, she has been involved in comprehensive drug development, spanning from non-clinical research to clinical trials and post-marketing activities for pharmaceuticals.